Skip to content

Supernus Pharmaceuticals

US · SUPN #2636 by market cap Listed 1970
28.61 +0.26 +0.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:48

About Supernus

Supernus, Inc. is a leading, recognized biopharmaceutical company focused on the development and commercialization of treatments for patients with central nervous system (CNS) disorders. The company’s portfolio of approved commercial products is designed to assist patients living with conditions such as opioid use disorder (OUD), attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease (PD)—specifically addressing motor fluctuations (such as "off" episodes) and motor impairment associated with the disease or its treatment (including levodopa-induced dyskinesia). Leveraging our robust commercial capabilities and scientific expertise, we remain committed to innovation, advancing a promising pipeline of novel investigational products aimed at delivering effective therapeutic outcomes for individuals with CNS disorders.

Founded
2005
CEO
Mr. Jack A. Khattar
Employees
778
Headquarters
Rockville, Maryland, United States of America
Fiscal year end
12-31
Website
supernus.com

Company profile

Exchange
US
Symbol
SUPN
Market-cap rank
#2636
Listing date
1970-01-01
Market cap
5.94B
Float cap
5.78B
Shares out
207.72M
Float shares
201.93M

Sectors & themes

Drug Manufacturers - Specialty & Generic Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.

Supernus Pharmaceuticals discussion 0 comments

Add a comment